This document is a patent application published by the USPTO, detailing a novel long-acting insulin compound. The application, identified as US20260085103A1, was filed on August 9, 2023, and published on March 26, 2026. It describes the compound's potential use in pharmaceutical compositions for treating various forms of diabetes, including type-I, type-II, and gestational diabetes.

As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in diabetes treatment and may impact intellectual property landscapes for pharmaceutical companies and researchers in the field. Companies involved in diabetes drug development should be aware of this filing for competitive intelligence and potential licensing opportunities.